AstraZeneca’s AZD9056 Shows Promise in Phase IIa Study on Moderate to Severe Crohn’s Disease
News
According to a recently published study, AstraZeneca’s AZD9056 – an orally-available purinergic receptor P2X7 antagonist, may be effective in symptom improvement in patients with moderate to severe Crohn’s disease. The study is ... Read more